Brazilian rare earths developer IMC produces first mixed carbonate, records high terbium recovery rates

NYSE-listed IMC Rare Earths (IMC) reported up to 95.2% terbium recovery rates from its Itarantim project in Brazil. The company also produced mixed rare earth carbonate on site. IMC tasked ANSTO Minerals for further metallurgical work. IMC highlights the project's high terbium grade and leachability, positioning Itarantim among top global projects. Rare earths are critical for technologies like AI, electric vehicles, and defence.

Original reporting
Published Sep 11, 2026, 8:46 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 11:31 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Brazilian rare earths developer IMC produces first mixed carbonate, records high terbium recovery rates — source image
Decision brief

The 30-second read

$IMCBullishLow
01

Why it matters

The data reduces technical risk and could improve the project's valuation, but commercial scaling and financing are still pending.

02

Market read

Positive test results may attract investors to the rare‑earth sector and support price expectations for terbium and related magnets.

03

What to watch

Capital requirements and permitting for large‑scale production remain uncertain.

Relevance 5/10Novelty 5/10Timing: today

Background

IMC Rare Earths (NYSE:IMC) reported new metallurgical testwork at its Itarantim ionic adsorption clay project in Brazil, achieving high terbium recovery and producing a mixed rare earth carbonate.

Company-level read

Ticker impact

$IMCBullishMedium confidence
Context

IMC Rare Earths disclosed lab-scale test results showing up to 95.2% terbium recovery and first on‑site mixed rare earth carbonate production.

Expected impact

Potential modest upside as investors reassess resource value.

Evidence & confidence

First‑time high recovery data reduces technical risk, but scale remains laboratory.

Market effects

Strengthens outlook for rare‑earth supply chain and related magnet manufacturers.

Highlights Brazil as a potential source of critical rare earths.

May influence global rare‑earth pricing and demand from EV and wind turbine sectors.

Counterpoint

Lab results may not translate to commercial scale; risk of over‑optimism.

Key entities

  • IMC Rare Earths

    NYSE‑listed rare‑earth developer reporting test results.

  • ANSTO Minerals

    Tasked with further quantitative metallurgical work.

Related articles

$BEMedAI 8/10

NTT Data Signs 900-Megawatt Bloom Energy Deal for Data Centers

NTT Data will deploy 900 MW of Bloom Energy's fuel-cell systems in data centers globally, starting in 2027. Bloom calls it their largest international project. NTT will use the systems as primary power. Bloom previously announced a deal with Oracle for up to 2.8 GW. The IEA projects global data-center electricity demand to double by 2030.

$MMSIMedAI 8/10

At six months, 92.7% of patients needed no repeat procedure for the treated dialysis-access blockage.

Merit Medical Systems (MMSI) reported 6-month data from the WRAP Global registry, showing 92.7% target lesion primary patency and 76.7% access circuit primary patency for its WRAPSODY CIE device in arteriovenous fistula patients. Results exceeded those from prior trials, according to the company. The device is FDA-approved and commercially available in the U.S., EU, and other regions.

$MTVAHighAI 8/10

MetaVia Reports 68% Placebo-Adjusted Liver Fat Reduction for DA-1726

MetaVia reported interim Phase 1 data for DA-1726, showing a 68% placebo-adjusted reduction in liver fat, 13.5% weight loss, and 0.24% HbA1c reduction. All participants with liver steatosis achieved MRI-PDFF below 5% by Day 109. No new gastrointestinal adverse events were reported after Week 9. Full Part 3A and 3B data is expected in Q1 2027, with a Phase 2 study planned for H2 2027.

$MTVAHighAI 8/10

MetaVia reports 68% liver fat reduction in phase 1 trial

MetaVia Inc. (MTVA) reported interim Phase 1 trial results for DA-1726, showing a 68% placebo-adjusted reduction in liver fat and 13.5% body weight reduction. The trial included 15 participants treated with DA-1726 and 4 on placebo. The company plans to report full data in Q1 2027 and initiate a Phase 2 study in H2 2027. Gastrointestinal adverse events were reported in 9 participants, with one serious case of severe vomiting.